The U.S. pharmaceutical industry is attempting to delay the timeline for Medicare's drug price negotiations following the ...

With fewer Part D plans and a $2,000 out-of-pocket cap, beneficiaries must rethink their Medicare drug coverage for 2025.

Seven lobbyists and executives who work with top pharmaceutical and biotech companies told Reuters they are pushing to delay ...

We need leaders to level with the American people about the challenges ahead — challenges Joe Biden understands well.

The lesson began over the weekend when the president’s son, Donald Trump Jr. — someone never tethered to the truth in his pursuit of liberal tears — reposted a social media message claiming that ...

The CMS estimated that coverage of the weight-loss drugs will cost the federal government about $25 billion for Medicare and ...

A record-low number of Medicare Part D plans could cause greater Medicare Advantage enrollment, which may not be a good thing ...

The Phoenix congressman had to push aside independent Kyrsten Sinema without hurting his chances against Republican Kari Lake ...

What tax policies is Trump likely to support? The following is a reasoned, practical and appropriately sardonic meditation on that question.

The Biden-Harris administration wants to expand coverage of anti-obesity medications in the Medicare and Medicaid programs.

In the US, buying Eliquis, one of the most popular blood thinning medications, costs over three times more than in the next ...

A new rule proposed by CMS presents alterations to the Medicare program, including expanded coverage for anti-obesity ...